About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, is the executive vice president and chief medical officer of CLL Society, 1 an organization he cofounded after his own diagnosis in 2005. Koffman is a ...

BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults and is currently incurable. Dr. Brian Koffman, chief medical officer and executive vice president of the CLL ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, of CLL Society, details the comprehensive multidisciplinary support for patients with chronic lymphocytic leukemia (CLL) at the European Hematology ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. For clinicians, I think it's more just ...

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys -CLL is one ...

“By partnering with CLL Society for the Test Before Treat campaign, we hope to educate people living with CLL on the importance of biomarker testing and how it can help chart a course for better ...